biomarker-trends-header.png

LDT for Thyroid Cancer Now Reimbursed for Over 110 Million Patients

by John Audette | Jul 09, 2013 | Marketing, News, Reimbursement

Company press release: Veracyte Receives Aetna Coverage for Its Afirma® Gene Expression Classifier for Use in Thyroid Cancer Diagnosis.

Post Mortem for Pathwork Diagnostics

Pathwork Dx Defunct; Future of Tissue of Origin Test Unclear from GenomeWeb

LDTs Clearly Remain Troublesome for FDA

by John Audette | Jul 01, 2013 | LDT Regulation, News, Regulation

Margaret Hamburg took the opportunity, at the end of a speech honoring a colleague at the annual meeting of the American Society of Clinical Oncology (ASCO), to make some pointed comments that should make LDT developers every more concerned about impending regulation of their wares.

   

December

Webinar: 

Pharmacovigilance and Safety Biomarkers

RECORDING
New Call-to-action
FREE REPORT

Subscribe for Updates

Download our Free IVD Trends Report